Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis (TRUNCATE-TB)
Sponsor: National University Hospital, Singapore
This PHASE2/PHASE3 trial investigates Tuberculosis, Pulmonary and is currently completed. National University Hospital, Singapore leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
Status: Unknown Status → Completed
-
Apr 2022 — Sep 2023 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Apr 2022 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 3 earlier versions
-
May 2019 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National University Hospital, Singapore
- Singapore Clinical Research Institute (SCRI)
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bandung, Indonesia , Bangkok, Thailand , Cebu, Philippines , Jakarta, Indonesia , Kampala, Uganda , Makassar, Indonesia , Malang, Indonesia , Manila, Philippines , Mbarara, Uganda , New Delhi, India and 4 more locations